8-K: Microbot Medical Wins Surgical Robotics Innovation Award

Microbot Medical received the Innovative Start-Up Award from Surgical Robotics Technology for its LIBERTY Endovascular Robotic System.

Summary

• Microbot Medical Inc. (NASDAQ: MBOT) was awarded the Innovative Start-Up Award by Surgical Robotics Technology (SRT).
• The award recognizes the LIBERTY Endovascular Robotic System as a groundbreaking, FDA-cleared, single-use, remotely operated robotic system.
• The company reports continued adoption and increased utilization of the LIBERTY system since its full market release in April 2026.
• The system is currently deployed at leading academic centers across seven U.S. states: NY, PA, FL, GA, MA, MI, and NC.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development that reinforces brand credibility and market adoption, though it lacks the financial data required for a higher score.

Positives

• Receipt of industry recognition validates the company's technological innovation and commercial progress.
• The LIBERTY system is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
• Reported expansion of the system's footprint into leading academic medical centers across multiple states.
• Successful transition from development to commercial market release.

Negatives

• The filing does not disclose specific financial performance metrics or revenue growth figures associated with the system's adoption.

Risks

• Inherent risks in the commercialization of the LIBERTY Endovascular Robotic System.
• Uncertainty regarding future regulatory pathways and approvals for new applications.
• Geopolitical risks, specifically disruptions resulting from hostilities involving Israel, Iran, and neighboring countries.
• Dependence on the maintenance and protection of intellectual property rights.

Future Outlook

The company remains focused on expanding the adoption of the LIBERTY System, executing its commercial strategy, advancing innovation, and delivering solutions for endovascular care.

Management Comments

• Harel Gadot, CEO: 'As the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, LIBERTY is helping redefine what is possible in endovascular intervention.'
• Harel Gadot, CEO: 'As we look ahead, we remain focused on expanding adoption of the LIBERTY System, executing our commercial strategy, advancing innovation, and delivering solutions that help shape the future of endovascular care.'

Industry Context

StockSavvy.ai notes that this award highlights the growing trend of single-use, remote-operated robotics in the endovascular space, positioning Microbot as a niche innovator competing against larger, multi-use robotic platforms.

Comparison to Industry Standards

• The LIBERTY system differentiates itself from traditional multi-use surgical robots by offering a single-use, remotely operated model.
• The company's focus on peripheral endovascular procedures targets a specific high-growth segment of the broader surgical robotics market.

Stakeholder Impact

• Shareholders may view the industry award as a positive indicator of commercial viability.
• Clinical partners and academic centers benefit from the validation of the technology they are utilizing.

Next Steps

• Continued expansion of the LIBERTY System adoption in academic centers.
• Execution of the ongoing commercial strategy.

Key Dates

Recommendation

While the award is a positive validation of the technology, the lack of concrete financial data regarding adoption rates and revenue makes a 'hold' appropriate until further earnings reports confirm commercial success.

Keywords

Microbot Medical, MBOT, Surgical Robotics, LIBERTY System, Endovascular, Medical Devices, FDA-cleared